SNK 2726
Alternative Names: SNK-2726Latest Information Update: 01 Jan 2025
Price :
$50 *
At a glance
- Originator SynerK
- Class Antihypertensives; Small interfering RNA
- Mechanism of Action Angiotensinogen expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hypertension
Most Recent Events
- 30 Dec 2024 Huadong Medicine and SynerK PharmaTech enters into an agreement to jointly develop SNK 2726 for the treatment of hypertension
- 30 Dec 2024 Preclinical trials in Hypertension in USA (SC), prior to December 2024
- 30 Dec 2024 Pharmacodynamics data from a preclinical trial in Hypertension released by Huadong Medicine